Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MELK | Q14680 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 6/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589725 | 1.00 | ALDH1A1 (0.59) | ALDH1A1MELKPNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL15671006 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MELKPNMTADRA2AADRA2B | |
| SCHEMBL30428318 | 0.93 | ALDH1A1 (0.59) | ALDH1A1MELKPNMTKDM4EMAPT | |
| SCHEMBL1026101 | 0.93 | ALDH1A1 (0.59) | ALDH1A1MELKPNMTKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL22654009 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MELKPNMTKDM4EMAPT | |
| SCHEMBL5578148 | 0.90 | ALDH1A1 (0.66) | ALDH1A1MELKPNMTKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28278640 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MELKPNMTKDM4EMAPT | |
| SCHEMBL3440731 | 0.89 | ALDH1A1 (0.69) | ALDH1A1MELKKDM4EMAPTDRD2 | |
| Hydrochloric Acid SCHEMBL7850413 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MELKKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL7560518 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MELKKDM4EMAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | claimed |
| EP-2247598-A1 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | claimed |
| EP-2114869-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| WO-2009095787-A1 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | claimed |
| EP-2068878-A2 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | claimed |
| CN-100435785-C | Pharmaceutical use of IAPP inhibiting compounds or pharmaceutically acceptable esters or pharmaceutically acceptable salts thereof | UNIV KINGSTON (CH) | 2008-11-26 | — | — | CN | claimed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | claimed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | claimed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | claimed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| EP-0989136-A1 | PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-03-29 | — | — | EP | claimed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-5491166-A | ENZYME INHIBITORS, VIRICIDES | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | ALDH1A1 681/4885MELK 3728/4885PNMT 1685/4885 |
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ALDH1A1 3661/4885MELK 1158/4885PNMT 722/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | ALDH1A1 2595/4885MELK 1478/4885PNMT 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.